GB2541483B - Antimicrobial peptide formulations - Google Patents

Antimicrobial peptide formulations

Info

Publication number
GB2541483B
GB2541483B GB1604893.6A GB201604893A GB2541483B GB 2541483 B GB2541483 B GB 2541483B GB 201604893 A GB201604893 A GB 201604893A GB 2541483 B GB2541483 B GB 2541483B
Authority
GB
United Kingdom
Prior art keywords
antimicrobial peptide
peptide formulations
formulations
antimicrobial
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB1604893.6A
Other versions
GB201604893D0 (en
GB2541483A (en
Inventor
Okhono Ulaeto David
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UK Secretary of State for Defence
Original Assignee
UK Secretary of State for Defence
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UK Secretary of State for Defence filed Critical UK Secretary of State for Defence
Publication of GB201604893D0 publication Critical patent/GB201604893D0/en
Publication of GB2541483A publication Critical patent/GB2541483A/en
Application granted granted Critical
Publication of GB2541483B publication Critical patent/GB2541483B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729Cationic antimicrobial peptides, e.g. defensins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005Antimicrobial preparations
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/19Dichroism
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/21Polarisation-affecting properties
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Birds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB1604893.6A 2015-03-30 2016-03-23 Antimicrobial peptide formulations Active GB2541483B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1505393.7A GB201505393D0 (en) 2015-03-30 2015-03-30 Antimicrobal peptide formulations

Publications (3)

Publication Number Publication Date
GB201604893D0 GB201604893D0 (en) 2016-05-04
GB2541483A GB2541483A (en) 2017-02-22
GB2541483B true GB2541483B (en) 2019-04-17

Family

ID=53178319

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB1505393.7A Ceased GB201505393D0 (en) 2015-03-30 2015-03-30 Antimicrobal peptide formulations
GB1604893.6A Active GB2541483B (en) 2015-03-30 2016-03-23 Antimicrobial peptide formulations

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GBGB1505393.7A Ceased GB201505393D0 (en) 2015-03-30 2015-03-30 Antimicrobal peptide formulations

Country Status (3)

Country Link
EP (1) EP3277261A1 (en)
GB (2) GB201505393D0 (en)
WO (1) WO2016156772A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3884089A4 (en) 2018-11-19 2023-04-05 Octet Medical, Inc. Device, systems, and methods of applying a treatment solution to a treatment site
CN113318054A (en) * 2021-05-10 2021-08-31 上海高庄生物科技有限公司 Cosmetic antiseptic composition and preparation method thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060162A2 (en) * 2000-02-15 2001-08-23 Ohio University Cationic, amphipathic beta-sheet peptides and uses thereof
WO2005090385A2 (en) * 2004-03-18 2005-09-29 Ansata Therapeutics, Inc. Compositions having antimicrobial activity and uses thereof
WO2006127715A1 (en) * 2005-05-23 2006-11-30 The Board Of Trustees Of The Leland Stanford Junior University Antimicrobial peptides
WO2006128289A1 (en) * 2005-06-02 2006-12-07 University Of Manitoba Use of brevinin-2r in the treatment of cancer
WO2008059011A1 (en) * 2006-11-15 2008-05-22 Scil Proteins Gmbh Artificial binding proteins based on a modified alpha helical region of ubiquitin
WO2008104777A2 (en) * 2007-03-01 2008-09-04 The University Of Bristol Peptide
US8530409B1 (en) * 2012-06-12 2013-09-10 Dipexium Pharmaceuticals LLC Stable pexiganan formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4942084B2 (en) * 2005-11-24 2012-05-30 学校法人順天堂 Apoptosis inhibitor
CN102091319B (en) * 2011-01-14 2012-11-07 哈尔滨工业大学 Use of toad peptide antibiotic for preparing medicaments for treating herpes zoster

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060162A2 (en) * 2000-02-15 2001-08-23 Ohio University Cationic, amphipathic beta-sheet peptides and uses thereof
WO2005090385A2 (en) * 2004-03-18 2005-09-29 Ansata Therapeutics, Inc. Compositions having antimicrobial activity and uses thereof
WO2006127715A1 (en) * 2005-05-23 2006-11-30 The Board Of Trustees Of The Leland Stanford Junior University Antimicrobial peptides
WO2006128289A1 (en) * 2005-06-02 2006-12-07 University Of Manitoba Use of brevinin-2r in the treatment of cancer
WO2008059011A1 (en) * 2006-11-15 2008-05-22 Scil Proteins Gmbh Artificial binding proteins based on a modified alpha helical region of ubiquitin
WO2008104777A2 (en) * 2007-03-01 2008-09-04 The University Of Bristol Peptide
US8530409B1 (en) * 2012-06-12 2013-09-10 Dipexium Pharmaceuticals LLC Stable pexiganan formulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Antimicrobial Agents and Chemotherapy, Vol. 60 No. 4, April 2016, ULAETO D. et al, "Destabilisation of alpha-helical structure in solution improves bactericidal activity of antimicrobial peptides: Opposite effects on bacterial and viral targets" *

Also Published As

Publication number Publication date
GB201604893D0 (en) 2016-05-04
GB201505393D0 (en) 2015-05-13
GB2541483A (en) 2017-02-22
EP3277261A1 (en) 2018-02-07
WO2016156772A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
IL289250A (en) Stabilized anti-microbial peptides
IL273541A (en) Formulations
IL268697A (en) Formulations
GB2573068B (en) Antimicrobial Compositions
IL269630A (en) Niraparib formulations
IL269621A (en) Niraparib formulations
IL273282A (en) Niraparib formulations
HK1254343A1 (en) Pharmaceutical formulations
HK1258803A1 (en) Lisinopril formulations
PL3253232T3 (en) Antimicrobial compositions
HK1254980A1 (en) Blended formulations
IL254794A0 (en) Pharmaceutical formulations
HK1257745A1 (en) Peptide composition
EP3197479A4 (en) Antimicrobial peptides
GB2528521B (en) Novel antimicrobial peptides
GB201405891D0 (en) Modified antimicrobial peptides
GB2541483B (en) Antimicrobial peptide formulations
EP3310363A4 (en) Antimicrobial formulations
GB201620963D0 (en) Antimicrobial peptides
IL254075B (en) Durable pest-repelling formulations
GB201714461D0 (en) Formulations
GB201621277D0 (en) Formulations
GB201618110D0 (en) Formulations
GB201616366D0 (en) Formulations
GB201615754D0 (en) Formulations